CRSP vs NKTX
CRSP: CRISPR Therapeutics is a biopharmaceutical company pioneering gene-editing therapies to treat and potentially cure severe genetic diseases using its proprietary CRISPR/Cas9 technology. NKTX: Nkarta is a clinical-stage biotechnology company pioneering off-the-shelf, engineered natural killer (NK) cell therapies to treat autoimmune diseases by depleting pathogenic B cells.
Side-by-side fundamentals
| Metric | CRSP | NKTX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $50.44 | $2.22 | |
| Market cap | $4.9B | $159M | |
| Net margin FY2025, SEC XBRL | -16569.8% | n/a | |
| Operating margin FY2025, SEC XBRL | -18933.6% | n/a | |
| ROE FY2025, SEC XBRL | -30.3% | -33.3% | CRSP higher |
| ROA FY2025, SEC XBRL | -25.7% | -25.8% | CRSP higher |
| Debt / equity as of 2026-09-03 | 0.34 | 0.00 | NKTX lower |
| Revenue growth (YoY) as of 2026-09-03 | -64.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +43.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.41 | 1.25 | |
| 1-year return as of 2026-10-08 close | -34.3% | +6.2% | NKTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.